Blood Test Approach Could Enable Personalized Cancer Immunotherapy Without Tumor Biopsy

A groundbreaking study published in Cancer Discovery demonstrates that cancer neoantigens and neoantigen-specific T cells can be identified directly from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells. This innovative blood-based approach eliminates the need for invasive tumor biopsies, potentially making personalized immunotherapy more accessible and less burdensome for cancer patients. The findings could revolutionize how doctors tailor cancer treatments to individual patients' unique tumor profiles. This advancement offers patients a less invasive alternative while maintaining the ability to develop highly targeted, personalized immunotherapies.